Literature DB >> 27976938

Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation.

David B Kantor1,2, Molly C McDonald1, Nicole Stenquist1, Blake J Schultz1, Craig D Smallwood1, Kyle A Nelson1,2, Wanda Phipatanakul1,2, Joel N Hirschhorn1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27976938      PMCID： PMC5215034          DOI： 10.1164/rccm.201606-1145LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  12 in total

1.  Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.

Authors:  Robert G Hamilton; Gregory V Marcotte; Sarbjit S Saini
Journal:  J Immunol Methods       Date:  2005-08       Impact factor: 2.303

2.  Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents.

Authors:  Jeremy J Wildfire; Peter J Gergen; Christine A Sorkness; Herman E Mitchell; Agustin Calatroni; Meyer Kattan; Stanley J Szefler; Stephen J Teach; Gordon R Bloomberg; Robert A Wood; Andrew H Liu; Jacqueline A Pongracic; James F Chmiel; Kathleen Conroy; Yadira Rivera-Sanchez; William W Busse; Wayne J Morgan
Journal:  J Allergy Clin Immunol       Date:  2012-01-12       Impact factor: 10.793

3.  Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children.

Authors:  David B Kantor; Nicole Stenquist; Molly C McDonald; Blake J Schultz; Marissa Hauptman; Craig D Smallwood; Kyle A Nelson; Matthew S Perzanowski; Elizabeth C Matsui; Wanda Phipatanakul; Joel N Hirschhorn
Journal:  J Allergy Clin Immunol       Date:  2016-06-15       Impact factor: 10.793

4.  An international observational prospective study to determine the cost of asthma exacerbations (COAX).

Authors:  Stephen Lane; Jesus Molina; Tadeusz Plusa
Journal:  Respir Med       Date:  2005-08-11       Impact factor: 3.415

5.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.

Authors:  William W Busse; Wayne J Morgan; Peter J Gergen; Herman E Mitchell; James E Gern; Andrew H Liu; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Jacqueline A Pongracic; James F Chmiel; Suzanne F Steinbach; Agustin Calatroni; Alkis Togias; Katherine M Thompson; Stanley J Szefler; Christine A Sorkness
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

6.  Predictors of symptoms are different from predictors of severe exacerbations from asthma in children.

Authors:  Ann Chen Wu; Kelan Tantisira; Lingling Li; Brooke Schuemann; Scott T Weiss; Anne L Fuhlbrigge
Journal:  Chest       Date:  2011-02-03       Impact factor: 9.410

7.  Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.

Authors:  Philip J Lowe; Panayiotis Georgiou; Janice Canvin
Journal:  Regul Toxicol Pharmacol       Date:  2014-12-08       Impact factor: 3.271

8.  Severe exacerbations in children with mild asthma: characterizing a pediatric phenotype.

Authors:  Christopher L Carroll; Craig M Schramm; Aaron R Zucker
Journal:  J Asthma       Date:  2008-08       Impact factor: 2.515

9.  Pediatric asthma admissions: chronic severity and acute exacerbations.

Authors:  Arnon Elizur; Leonard B Bacharier; Robert C Strunk
Journal:  J Asthma       Date:  2007-05       Impact factor: 2.515

Review 10.  Acute severe asthma.

Authors:  E R McFadden
Journal:  Am J Respir Crit Care Med       Date:  2003-10-01       Impact factor: 21.405
View more
  15 in total

Review 1.  New Insights into Cockroach Allergens.

Authors:  Anna Pomés; Geoffrey A Mueller; Thomas A Randall; Martin D Chapman; L Karla Arruda
Journal:  Curr Allergy Asthma Rep       Date:  2017-04       Impact factor: 4.806

2.  Gene-Environment Interactions Associated with the Severity of Acute Asthma Exacerbation in Children.

Authors:  David B Kantor; Wanda Phipatanakul; Joel N Hirschhorn
Journal:  Am J Respir Crit Care Med       Date:  2018-03-01       Impact factor: 21.405

3.  Reply.

Authors:  David B Kantor; Wanda Phipatanakul; Joel N Hirschhorn
Journal:  J Allergy Clin Immunol       Date:  2017-03-06       Impact factor: 10.793

Review 4.  Management of Severe Asthma before Referral to the Severe Asthma Specialist.

Authors:  Tara F Carr; Monica Kraft
Journal:  J Allergy Clin Immunol Pract       Date:  2017 Jul - Aug

5.  Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.

Authors:  Ann Esquivel; William W Busse; Agustin Calatroni; Alkis G Togias; Kristine G Grindle; Yury A Bochkov; Rebecca S Gruchalla; Meyer Kattan; Carolyn M Kercsmar; G Khurana Hershey; Haejin Kim; Petra Lebeau; Andrew H Liu; Stanley J Szefler; Stephen J Teach; Joseph B West; Jeremy Wildfire; Jaqueline A Pongracic; James E Gern
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

6.  Evolving concepts in how viruses impact asthma: A Work Group Report of the Microbes in Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Matthew C Altman; Avraham Beigelman; Christina Ciaccio; James E Gern; Peter W Heymann; Daniel J Jackson; Joshua L Kennedy; Kirsten Kloepfer; Robert F Lemanske; Laurie M McWilliams; Lyndsey Muehling; Christy Nance; R Stokes Peebles
Journal:  J Allergy Clin Immunol       Date:  2020-01-09       Impact factor: 14.290

7.  Fluid Balance Is Associated with Clinical Outcomes and Extravascular Lung Water in Children with Acute Asthma Exacerbation.

Authors:  David B Kantor; Eliotte L Hirshberg; Molly C McDonald; John Griffin; Tess Buccigrosso; Nicole Stenquist; Craig D Smallwood; Kyle A Nelson; David Zurakowski; Wanda Phipatanakul; Joel N Hirschhorn
Journal:  Am J Respir Crit Care Med       Date:  2018-05-01       Impact factor: 30.528

Review 8.  Childhood asthma heterogeneity at the era of precision medicine: Modulating the immune response or the microbiota for the management of asthma attack.

Authors:  Stéphanie Lejeune; Antoine Deschildre; Olivier Le Rouzic; Ilka Engelmann; Rodrigue Dessein; Muriel Pichavant; Philippe Gosset
Journal:  Biochem Pharmacol       Date:  2020-05-22       Impact factor: 5.858

Review 9.  Promising approaches for the treatment and prevention of viral respiratory illnesses.

Authors:  Nikolaos G Papadopoulos; Spyridon Megremis; Nikolaos A Kitsioulis; Olympia Vangelatou; Peter West; Paraskevi Xepapadaki
Journal:  J Allergy Clin Immunol       Date:  2017-07-21       Impact factor: 10.793

Review 10.  Asthma and viral infections: An intricate relationship.

Authors:  Irene Mikhail; Mitchell H Grayson
Journal:  Ann Allergy Asthma Immunol       Date:  2019-07-02       Impact factor: 6.347
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.